MicroRNA‑548ac induces apoptosis in laryngeal squamous cell carcinoma cells by targeting transmembrane protein 158

Song,Fucun; Yang,Yang; Jixiang Liu,Jixiang

doi:10.3892/ol.2020.11930

MicroRNA‑548ac induces apoptosis in laryngeal squamous cell carcinoma cells by targeting transmembrane protein 158

Authors:
- Fucun Song
- Yang Yang
- Jixiang Jixiang Liu
View Affiliations

Affiliations: Department of Otolaryngology Head and Neck Surgery, Tianjin Union Medical Center, Tianjin 300121, P.R. China
Published online on: July 29, 2020 https://doi.org/10.3892/ol.2020.11930
Article Number: 69
Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Laryngeal cancer is a common head and neck cancer that effects the quality of life of those affected. Early diagnosis and treatment are vital to minimize the harmful effects of laryngeal cancer, which can improve the survival rate of patients following surgery and retain the voice function of the larynx. The purpose of the present study was to explore the molecular mechanism of the development of laryngeal cancer and to determine the biomarker for the diagnosis and treatment of laryngeal cancer. Reverse transcription‑quantitative PCR (RT‑qPCR) and The Cancer Genome Atlas database analysis were used to confirm high expression of TMEM158 in laryngeal cancer. The effects of TMEM158 and miR‑548ac was investigated through in vitro and in vivo assays (MTT assay, colony‑formation assay, flow cytometry assay, western blotting and tumor xenograft assay). Luciferase reporter assay, western blotting and RTq‑PCR were used to confirm that miR‑548 directly targeted the 3'‑untranslated region of TMEM158 and inhibited TMEM158 expression. Taken together, the present results suggest that miR‑548ac functions as a crucial cancer suppressor in laryngeal cancer, which induces apoptosis in laryngeal cancer cells by suppressing TMEM158. Thus, miR‑548ac may be a potential target for the treatment of laryngeal cancer.

View Figures

View References

1	Beibei Y, Rong Y, Yunfei Y and Wenchao Z: Research progress regarding surgical margins, molecular margins, and prognosis of laryngeal carcinoma. Ear Nose Throat J 145561320903146. 2020.(Epubahead of print). View Article : Google Scholar
2	Olaleye O, Siddiq S, Ekrikpo U and Kazi R: Regional differences in incidence and mortality trends in cancers of the larynx, thyroid, oral cavity and pharynx in England and Scotland: 1975–2002. Open Epidemiol J. 3:70–78. 2013. View Article : Google Scholar
3	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
4	Steuer CE, El-Deiry M, Parks JR, Higgins KA and Saba NF: An update on larynx cancer. CA Cancer J Clin. 67:31–50. 2017. View Article : Google Scholar : PubMed/NCBI
5	Menicagli R, Bolla G, Menicagli L and Esseridou A: The possible role of diabetes in the etiology of laryngeal cancer. Gulf J Oncolog. 1:44–51. 2017.PubMed/NCBI
6	Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, Delgado MD, Leon J, Hara E and Serrano M: Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res. 273:127–137. 2002. View Article : Google Scholar : PubMed/NCBI
7	Cheng Z, Guo J, Chen L, Luo N, Yang W and Qu X: Overexpression of TMEM158 contributes to ovarian carcinogenesis. J Exp Clin Cancer Res. 34:752015. View Article : Google Scholar : PubMed/NCBI
8	Mohammed Ael S, Eguchi H, Wada S, Koyama N, Shimizu M, Otani K, Ohtaki M, Tanimoto K, Hiyama K, Gaber MS and Nishiyama M: TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells. Exp Lung Res. 38:463–474. 2012. View Article : Google Scholar : PubMed/NCBI
9	Fu Y, Yao N, Ding D, Zhang X, Liu H, Ma L, Shi W, Zhu C and Tang L: TMEM158 promotes pancreatic cancer aggressiveness by activation of TGFβ1 and PI3K/AKT signaling pathway. J Cell Physiol. 235:2761–2775. 2020. View Article : Google Scholar : PubMed/NCBI
10	Hummel R, Maurer J and Haier J: MicroRNAs in brain tumors: A new diagnostic and therapeutic perspective? Mol Neurobiol. 44:223–234. 2011. View Article : Google Scholar : PubMed/NCBI
11	Rouleau S, Glouzon JS, Brumwell A, Bisaillon M and Perreault JP: 3′ UTR G-quadruplexes regulate miRNA binding. RNA. 23:1172–1179. 2017. View Article : Google Scholar : PubMed/NCBI
12	Xiao X, Cao Y and Chen H: Profiling and characterization of microRNAs responding to sodium butyrate treatment in A549 cells. J Cell Biochem. 119:3563–3573. 2018. View Article : Google Scholar : PubMed/NCBI
13	Liang T, Guo L and Liu C: Genome-wide analysis of mir-548 gene family reveals evolutionary and functional implications. J Biomed Biotechnol. 2012:6795632012. View Article : Google Scholar : PubMed/NCBI
14	Wang Z, Wu X, Hou X, Zhao W, Yang C, Wan W and Chen L: MiR-548b-3p functions as a tumor suppressor in lung cancer. Lasers Med Sci. 35:833–839. 2020. View Article : Google Scholar : PubMed/NCBI
15	Shi Y, Qiu M, Wu Y and Hai L: MiR-548-3p functions as an anti-oncogenic regulator in breast cancer. Biomed Pharmacother. 75:111–116. 2015. View Article : Google Scholar : PubMed/NCBI
16	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
17	Tashiro K, Kuroki N, Einama T, Iwasaki T, Miyata Y, Aosasa S, Inoue Y, Takahashi Y, Ogata S, Ueno H, et al: Prognostic significance of regional lymph node metastasis according to station in ampullary carcinoma. J Hepatobiliary Pancreat Sci. 2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
18	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
19	Mellis D and Caporali A: MicroRNA-based therapeutics in cardiovascular disease: Screening and delivery to the target. Biochem Soc Trans. 46:11–21. 2018. View Article : Google Scholar : PubMed/NCBI
20	Qadir MI and Faheem A: MiRNA: A diagnostic and therapeutic tool for pancreatic cancer. Crit Rev Eukaryot Gene Expr. 27:197–204. 2017. View Article : Google Scholar : PubMed/NCBI
21	Iglesias D, Fernandez-Peralta AM, Nejda N, Daimiel L, Azcoita MM, Oliart S and Gonzalez-Aguilera JJ: RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet. 167:138–144. 2006. View Article : Google Scholar : PubMed/NCBI
22	Zirn B, Samans B, Wittmann S, Pietsch T, Leuschner I, Graf N and Gessler M: Target genes of the WNT/beta-catenin pathway in Wilms tumors. Genes Chromosomes Cancer. 45:565–574. 2006. View Article : Google Scholar : PubMed/NCBI
23	Liu L, Zhang J, Li S, Yin L and Tai J: Silencing of TMEM158 inhibits tumorigenesis and multidrug resistance in colorectal cancer. Nutr Cancer. 72:662–671. 2020. View Article : Google Scholar : PubMed/NCBI
24	Kura B, Kalocayova B, LeBaron TW, Frimmel K, Buday J, Surovy J and Slezak J: Regulation of microRNAs by molecular hydrogen contributes to the prevention of radiation-induced damage in the rat myocardium. Mol Cell Biochem. 457:61–72. 2019. View Article : Google Scholar : PubMed/NCBI
25	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
26	Correia de Sousa M, Gjorgjieva M, Dolicka D, Sobolewski C and Foti M: Deciphering miRNAs' Action through miRNA Editing. Int J Mol Sci. 20:62492019. View Article : Google Scholar